依帕司他联合贝前列素钠在糖尿病患者中的临床效果及对神经缺损的影响
| 作者: |
1谢宇,
2杨振环
1 华北医疗健康集团峰峰总医院内分泌科，河北 邯郸 065200 2 华北医疗健康集团峰峰总医院骨科，河北 邯郸 065200 |
| 通讯: |
谢宇
Email: xieyu1981_01@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.07.014 |
摘要
目的：探讨依帕司他联合贝前列素钠在糖尿病患者中的临床效果及对神经缺损的影响。方法：选2017年5月至2019年5月冀中能源峰峰集团有限公司总医院收治的104例糖尿病并发神经缺损患者作为研究对象，按照随机数表法随机分为研究组与对照组，每组各52例，对照组临床治疗采用依帕司他，研究组在对照组基础上应用贝前列素钠治疗，分析其对患者神经缺损的影响。结果：研究组和对照组一般资料相比，差异无统计学意义(P>0.05)；研究组空腹血糖(fasting blood-glucose，FPG)、餐后2 h血糖(2hPG)、三酰甘油(TG)、胆固醇(TC)以及低密度脂蛋白(low-density lipoprotein，LDL-C)水平与对照组的差异无统计学意义(P>0.05)；治疗前研究组正中神经、腓总神经、胫骨神经的运动神经传导速度(motor nerve conduction velocity，MNCV)和感觉神经传导速度(sensory nerve conduction velocity，SNCV)与对照组的差异无统计学意义(均P>0.05)；治疗后研究组MNCV和SNCV的改善情况更加明显(P<0.05)，研究组疗效高于对照组(均P<0.05)；治疗前，两组患者的炎症指标血清肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)的差异无统计学意义(均P>0.05)，治疗后，两组患者的炎症指标均明显降低，且研究组患者的炎症指标明显低于对照组，差异有统计学意义(P<0.05)；治疗前，两组患者的应激反应指标氧化物歧化酶(superoxide dismutase，SOD)、丙二醛(malondialdehyde，MDA)的差异无统计学意义(均P>0.05)，治疗后，两组患者的应激反应指标SOD均明显升高，且研究组患者的SOD指标明显高于对照组，差异有统计学意义(均P<0.05)，两组患者的应激反应指标MDA均明显降低，且研究组患者的MDA指标明显低于对照组，差异有统计学意义(均P<0.05)。结论：在针对糖尿病神经缺损患者的治疗过程中，采用依帕司他联合贝前列素钠治疗可以促进患者的神经功能恢复，提高治疗效果，且对于患者的血糖控制情况不会造成明显影响，可在临床上进一步推广应用。
关键词：
依帕司他；贝前列素钠；糖尿病；神经缺损；临床疗效；神经功能
Clinical effect of epalrestat combined with beraprost sodium in diabetic patients and its effect on nerve defect
CorrespondingAuthor: XIE Yu Email: xieyu1981_01@163.com
DOI: 10.3978/j.issn.2095-6959.2021.07.014
Abstract
Objective: To investigate the clinical effect of epalrestat combined with beraprost sodium in diabetic patients and its effect on nerve defects. Methods: A total of 104 cases of diabetic patients with nerve defect from May 2017 to May 2019 were selected as the research object, and randomly divided into two groups according to the random number table method (n=52 for each). The control group was treated with epalrestat, and the study group was treated with beraprost sodium on the basis of the control group, and the effect on the patients with nerve defect was analyzed. Results: There was no significant difference in the general information between the study group and the control group (all P>0.05); there was no significant difference in FPG, 2hPG, TG, TC and LDL-C between the study group and the control group (all P>0.05); before treatment, there was no significant difference in motor nerve conduction velocity (MNCV) and sensory nerve conduction velocity (SNCV) between the study group and the control group (all P>0.05), after treatment, the improvement of MNCV and SNCV in the study group was more obvious in the study group (P<0.05), and the effect in the study group was higher than that in the control group (all P<0.05). Before treatment, there was no significant difference in the inflammatory indexes of TNF-α and IL-6 between the two groups (all P>0.05); after treatment, the inflammatory indexes of the two groups were significantly decreased, and the inflammatory indexes of the study group were significantly lower than those of the control group (all P<0.05), the difference was statistically significant (all P<0.05); before treatment, there was no significant difference between the two groups in the indexes of SOD and MDA (all P>0.05); after treatment, the indexes of SOD in the two groups were significantly increased (P<0.05), and the indexes of SOD in the study group were significantly higher than those in the control group (all P<0.05); the indexes of MDA in the two groups were significantly decreased, and the indexes of MDA in the study group were significantly increased, the difference was statistically significant (all P<0.05). Conclusion: In the treatment of patients with diabetic nerve defect, epalrestat combined with beraprost sodium treatment can promote the recovery of neurological function, improve the treatment effect, and will not have a significant impact on the blood glucose control of patients, so it should be further promoted in clinical application.
Keywords：
epalrestat; beraprost sodium; diabetes mellitus; nerve defect; clinical efficacy; nerve function